Skip to main content

Table 1 Sensitivity of the cell lines to CEP-37440

From: The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells

Cell line Type Subtype GI50 (nM) Reference
   ESR PgR ErbB2   
FC-IBC02 IBC Neg Neg Neg 91 [10]
KPL4 IBC Neg Neg Post ~900 [41]
SUM190 IBC Neg Neg Post 890 [42]
MDA-IBC03 IBC Neg Neg Post 1860 [43]
SUM149 IBC Neg Neg Neg >3000 [42]
MCF-12A Normal-like breast epithelial cells Neg Neg Neg 1516 [44]
MCA-10A Normal-like breast epithelial cells Neg Neg Neg 1700 [45]
MDA-MB-231 BC (non-IBC) Neg Neg Neg 1930 [46]
MDA-MB-468 BC (non-IBC) Neg Neg Neg 1275 [46]
  1. Inflammatory breast cancer (IBC), breast cancer (BC) non-IBC, and normal-like breast epithelial cell lines were grown in the presence of different concentrations of CEP-37440 (cell proliferation assays). The GI50 indicate the CEP-37440 concentration required to reduce growth rates to 50 % of the maximum rate. The GI50 was calculated for each cell line at t = 144 h of CEP-37440 treatment using sigmoidal dose response curve (variable slope) in GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA)
  2. ESR estrogen receptor, PgR progesterone receptor, ErbB2 epidermal growth factor receptor 2